New Study Shows Improved Peritoneal Mesothelioma Survival

Patients with malignant peritoneal mesothelioma who completed a novel, two-stage cytoreduction and intraperitoneal chemotherapy regimen had a median overall survival of 6.65 years. Almost 30 percent of those patients had a survival estimate of more than 10 years after the second stage of treatment, according to a study published recently in the Annals of Surgical Oncology. The study involved 113 patients from New York-Presbyterian Hospital/Columbia University Medical Center. Researchers demonstrated the therapeutic advances concerning this once unbeatable cancer. While progress has been slow in improving current pleural mesothelioma treatments, research has shown more significant advances in novel therapies for the peritoneal type of the cancer. “There is hope out there for these [peritoneal] patients today,” Dr. Michael Kluger, assistant professor of surgery and leader of the mesothelioma program at Columbia’s medical center, told Asbestos.com. “People are living a long time now when they are appropriately treated from the get-go. It is night and day from where it once was.” Second Surgery Is Helpful The study objective was to determine the time and predictors of mesothelioma tumor recurrence in optimally treated patients. The median, recurrence-free survival was 38.5 months, and 80 percent of the patients with recurrence received some form of iterative treatment. “Even when there is recurrence, there is opportunity for retreatment of this disease,” Kluger stre...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Columbia University Medical Center Dr. Michael Kluger Dr. Paul Sugarbaker HIPEC for peritoneal mesothelioma New York-Presbyterian Hospital peritoneal mesothelioma treatment Source Type: news